MedPath

Evaluation of safety & Efficacy of cosmetic product

Not Applicable
Registration Number
CTRI/2023/10/058850
Lead Sponsor
GLENMARK PHARMACEUTICALS LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Indian Female subjects

2.Healthy subjects

3.Age 18 years and above (up to 60 years).

4.Skin is healthy on the studied anatomic unit

5.Human subjects with melasma

Exclusion Criteria

1.Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.

2.Having refused to give her assent by not signing the consent form.

3.Taking part in another study liable to interfere with this study.

4.Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)

5.Having progressive asthma.

6.Being epileptic.

7.Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)

8.Having cutaneous hypersensitivity

9.Having a diagnosed or highly probable allergy to one or several compounds of cosmetic products.

10.Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol)

11.Having consumed caffeine-based products (coffee, cola, tea …), alcohol, highly spiced foods and/or smoked in the two hours preceding the measurements.

12.Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

13.Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit

14.Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Melasma reductionTimepoint: Day 0, Day 14, Day 28, Day 56 and Day 112
Secondary Outcome Measures
NameTimeMethod
Change in quality of lifestyle related to melasma and number of Events, cosmetic acceptibility, reduction in melanin content of pigmentary spotsTimepoint: Day 0, Day 14, Day 28, Day 56 and Day 112
© Copyright 2025. All Rights Reserved by MedPath